Search

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Trends & Insights

News

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Something learnt

We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.

Bringing Value to the Healthcare Community

Our fundamental mission is to make the lives of patients better.

3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US

Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.

New Documentary Highlights Ranch’s Commitment to Cattle Health

Transboundary and Emerging Diseases | Boehringer Ingelheim US

Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

Submit Your Partnering Opportunity

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Accountability, Agility, Intrapreneurship

How we work together

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Click here to read more on the possible signs of diabetes in your feline friends, including how to identify and prevent potential symptoms and risks.

History of our Logo | Corporate Profile | Boehringer Ingelheim US

The logo used by Boehringer Ingelheim today is a stylized depiction of the central section of the imperial palace of Charlemagne.

Striving to revolutionize mental health research

World Mental Health Day: We are committed to transforming the mental health landscape through precision psychiatry

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

Meet the Animal Health Partnering Team

Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.

Working Together in Human Health

Netherlands

Sites Around the World

Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Trends & Insights

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Outlook for Partnering in Animal Health 2024

Something learnt

Bringing Value to the Healthcare Community

3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US

New Documentary Highlights Ranch’s Commitment to Cattle Health

Transboundary and Emerging Diseases | Boehringer Ingelheim US

Supply Chain Scholarship for Cowtribe

BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

S&P Animal Health Partnering Oct 2023

Submit Your Partnering Opportunity

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

Accountability, Agility, Intrapreneurship

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

History of our Logo | Corporate Profile | Boehringer Ingelheim US

Striving to revolutionize mental health research

Our Curiosity Never Stops | Boehringer Ingelheim US

Meet the Animal Health Partnering Team

Working Together in Human Health

Netherlands

Sites Around the World